LUIJTEN, Maartje M W, van Weelden Willem JAN, Roy I LALISANG, Johan BULTEN, Kristina LINDEMANN, Heleen J VAN BEEKHUIZEN, Hans TRUM, Dorry BOLL, Henrica M J WERNER, Luc R C W VAN LONKHUIJZEN, Refika YIGIT, Camilla KRAKSTAD, Petronella O WITTEVEEN, Khadra GALAAL, Alexandra A VAN GINKEL, Eliana BIGNOTTI, Vít WEINBERGER, Sanne SWEEGERS, Ane Gerda Z ERIKSSON, Diederick M KEIZER, van de Stolpe ANJA, Andrea ROMANO a Johanna M A PIJNENBORG. Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma. Cancers. BASEL: MDPI, 2024, roč. 16, č. 11, s. 1-19. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers16112084.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
Autoři LUIJTEN, Maartje M W, van Weelden Willem JAN, Roy I LALISANG, Johan BULTEN, Kristina LINDEMANN, Heleen J VAN BEEKHUIZEN, Hans TRUM, Dorry BOLL, Henrica M J WERNER, Luc R C W VAN LONKHUIJZEN, Refika YIGIT, Camilla KRAKSTAD, Petronella O WITTEVEEN, Khadra GALAAL, Alexandra A VAN GINKEL, Eliana BIGNOTTI, Vít WEINBERGER (203 Česká republika, domácí), Sanne SWEEGERS, Ane Gerda Z ERIKSSON, Diederick M KEIZER, van de Stolpe ANJA, Andrea ROMANO a Johanna M A PIJNENBORG.
Vydání Cancers, BASEL, MDPI, 2024, 2072-6694.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30214 Obstetrics and gynaecology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.200 v roce 2022
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/cancers16112084
UT WoS 001246772500001
Klíčová slova anglicky endometrial cancer; hormone receptor; tumour location
Štítky 14110240, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 2. 7. 2024 08:30.
Anotace
Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC. Methods: Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0-10%, 10-50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor. Results: There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations (p = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS. Conclusions: A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.
VytisknoutZobrazeno: 17. 7. 2024 23:42